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In 2004, the US Surgeon General launched the Family History Public Health Initiative to 
increase awareness and discussions regarding family health history (FHx). FHx reflects the 
combined influences of shared genetic, behavioral, and environmental factors in families. 
The collection and use of FHx have already been shown to be useful in risk assessment and 
preventive intervention for cardiovascular disease, osteoporosis, and cancer surveillance/
chemoprevention, to name a few.1–3 Yet many segments of the population lack adequate 
access to the genetic component of FHx that might inform their health management. Here, 
we focus on adoptees, whose lack of genetic FHx normally reflects separation from 
biological parents as an inherent feature of adoption. However, our fundamental point is 
applicable to anyone who lacks access to genetic FHx information, which can occur for 
many reasons. Lack of genetic FHx is not inconsequential; for example, a recent Swedish 
study of adoptees emphasizes the importance of genetic factors over environmental factors 
for several cancers.4 Current genetic testing capabilities are at a stage where it is legitimate 
to ask, “Could targeted genetic analysis offer any potential benefit for those individuals who 
have no or limited access to family history, such as many adoptees?” And might the 
potential benefits and risks of genetic analysis differ between adoptees and those with access 
to their family history information?
According to US Census data (2000), adoptees account for more than 2.5% of the US 
population (7.8 million). Worldwide, the United Nations estimates that at least 260,000 
children are adopted annually, and the number of children globally who have lost both 
parents is more than 60 times this number.5 Although some adoptees have access to family 
history information (for example, through open adoption or biological relative adoption), 
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many do not. One study found that for adoptees in general, family medical information was 
available for less than half of birth fathers.6 For international adoptees (currently one-quarter 
of adoptions),7 this problem is exacerbated not only by logistical difficulties but also by 
well-established problems surrounding the limitations of medical records in many countries 
from which international adoptions occur. For nearly two-thirds of international adoptees, no 
written medical records exist, even for basic things such as vaccination status.8,9 Moreover, 
even adoptees with access to some FHx information often lack ongoing, iterative refinement 
of this knowledge available to biologically related families who have regular, multi-
generational interaction.
Clinical actionability of FHx in practice is often seen in situations in which the pattern of 
disease in the family suggests the presence of a genetic disorder and indicates the need for 
earlier screening or other interventions. Many adoptees do not have access to this potentially 
lifesaving information. However, emerging genomic technologies are beginning to offer the 
possibility of accessing some of this medically actionable genetic information. An important 
point of similarity between genetic data and family history is that both have the greatest 
clinical impact on medical care when they serve to indicate an uncommon, but dramatic, risk 
such as that indicated by a strong family history of early diagnosis of breast cancer, colon 
cancer, or the like (knowledge of which can lead to recommendations for earlier screening 
or overtly preventive intervention). It is in several of these areas where the strongest gene–
disease associations lie, such as for breast cancers and colorectal cancers. Although genetic 
analysis is unlikely to provide a replacement for family history when available, if properly 
targeted and interpreted, such analysis may have the potential to provide useful information 
regarding health risks when no information currently exists. Given an inability to realize 
family history–derived health benefits (i.e., a need for earlier screening or interventions) by 
many adoptees, it is critical to evaluate the potential of carefully considered genetic 
evaluation in this population.
APPLICATION OF GENETIC TECHNOLOGIES FOR HEALTH RISK 
IDENTIFICATION
Despite the potential described, uncertainty exists regarding the ability of genomic analyses 
of common genetic variants to play a role in the identification of inherited disease risk. 
Some of this surrounds previous studies that, rather predictably, found genome-wide 
association studies testing to be far less useful than family history alone but of some possible 
use as a supplement to family history.10,11 Also, the most successful applications of genetic 
testing often involve testing multiple related individuals across several generations, which is 
something quite difficult to realize in practice. Also problematic is that many genes confer 
intermediate degrees of increased disease risk (e.g., CHEK2) and that an individual’s actual 
risk remains dependent on a variety of factors, including family history.10 Thus, although 
integrating family history information and genomic data is optimal, not everyone has an 
accurate and/or complete family history or access to biological relatives who could 
participate. Moreover, interpretation of the genome is currently limited. The inevitable 
discovery of incidental findings is one of the most controversial and problematic issues in 
genomic medicine, and false reassurance from negative reports or overreaction to positives 
May et al. Page 2
Genet Med. Author manuscript; available in PMC 2016 January 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
from indeterminate or low-prevalence gene–disease associations (exacerbated by the high 
number of variants of unknown significance) continue to challenge genetic clinicians.
Given these limitations, the greatest potential for use of genomic information in the absence 
of family history may be derived from analysis of a limited number of highly penetrant, 
well-established, and actionable gene–disease associations that confer relatively high levels 
of risk. As discussed previously, such variants are often most recognizable as “mapping 
onto” those conditions commonly thought of as identifiable through traditional FHx. The 
number of genes to be analyzed under such an approach would be small given the currently 
poor potential for robust prevention of most conditions. However, like newborn screening 
panels used in many states, such information may prove critically valuable to a subset of 
individuals.12
A number of important issues will need to be addressed to realize the promise of such an 
approach. For example, it might well be the case that when we identify an individual with 
the BRCA1 mutation who has no positive family history of disease (in our context, because 
they lack family health history information), the risk for that person may be somewhat lower 
than that for an individual with, for example, multiple relatives who had breast cancer. Lack 
of knowledge about FHx will thus complicate counseling for BRCA-positive individuals 
(e.g., how do we discuss options like a risk-reducing bilateral mastectomy with a woman 
who is positive for BRCA1 but has no positive family history indicators?). In summary, for 
many gene–disease associations, interpretation of risk is partly dependent on contexts that 
may be different for adoptees lacking access to FHx, and thus may require rethinking how 
we approach both counseling and risk stratifications within clinical reports.
Nonetheless, for people who do not have access to FHx, a conservative approach consisting 
of targeted analysis of highly actionable genes to discover mutations that would lead to clear 
clinical recommendations designed to avert a significant threat to health may be useful.
Several examples of targeted panels that might serve as starting points for FHx information 
for adoptees have already been proposed. Lists identified by GeneScreen,13 the Clinical 
Sequencing Exploratory Research Consortium,14 and the American College of Medical 
Genetics and Genomics working group on incidental findings15 all identify highly penetrant, 
actionable gene disease associations that have high morbidity and/or mortality. Each of these 
has its own controversies and limitations, but they represent an excellent starting point to 
define a subset of targeted gene testing that may be useful to adoptees. The list of genes and 
conditions identified would likely be modified for adult adoptees due to differing contexts 
for understanding “actionability” in adult adoptees versus the general population. For 
example, when the strength of gene–disease association is highly dependent on 
interpretation in the context of family history, the specific mutation in question might be less 
appropriate for adoptees than for the general public. In addition, some FHx information is 
important not for health screening, but for other purposes, e.g., reproduction. For example, 
Tay-Sachs is perhaps the most well-known hereditary condition for which lack of genetic 
information (in this case, that of ancestry) might be relevant. The exact list of genes that 
would be optimal for analysis will depend on a variety of factors, including considerations 
of penetrance, efficacy of prevention, and individual choice. In summary, actionability is a 
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contextual assessment that will require careful consideration of how a lack of traditional 
FHx information might reframe our understanding of it.
CONCLUSION
At this time, the role of genomic analysis is most certainly an imperfect substitute for FHx. 
However, traditional FHx has significant limitations, too, in that it is the exception rather 
than the norm wherein FHx dramatically changes the approach to clinical care for most 
individuals. However, those cases where FHx does have utility are significant and such 
information can be life-saving. Therefore, mitigating lack of access to FHx through the 
thoughtful provision of targeted, highly selected genomic information could represent a 
valuable application of this newly emerging technology to the adopted population. 
Prospective, targeted analysis of selected genes in this population should be explored to 
assess its benefits and risks, both of which might vary from the broad population with access 
to FHx. Its application may be appropriate for assessing risk in only a few conditions to 
begin with; however, as predictive capacity improves and as preventive modalities are 
eventually developed for an expanding set of genetic disorders, its benefits may expand. 
Studies of how such populations perceive and integrate targeted genomic information into 
their lives and their healthcare will be key to understanding the value of genetic information 
obtained outside the traditional context of known family health history.
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